| For: | Huang XP, Liu YJ, Lin SW, Shao YF, Qiu F, Qiu QW, Xu ZK, Chen JX, Chen LH, Lin ZQ, Dai WH, Zhang MQ, Jiang Q, Xiao ZQ, Cheng XX, Zhang XF, You WB, Chen W, Li LQ, Lin WX, Wang YF, Lai FJ, Chen LQ, Huang ZH, Zheng WQ, Wei JQ, Lin ZH. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: A prospective, multicenter, randomized, two-stage study. World J Gastroenterol 2024; 30(27): 3304-3313 [PMID: 39086752 DOI: 10.3748/wjg.v30.i27.3304] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v30/i27/3304.htm |
| Number | Citing Articles |
| 1 |
Karolina Kornatowska, Edyta Hańczyk, Dawid Piecuch, Szymon Kopciał, Natalia Pawelec, Weronika Mazur, Mateusz Tyniec, Kamal Morshed. A Novel Approach to H. pylori Eradication: A Narrative Review of Vonoprazan-Based Therapies. Gastroenterology Insights 2025; 16(3) doi: 10.3390/gastroent16030035
|
| 2 |
Zhaoli Ma, Shiling Wang, Furui Wang, Qian Ren.
Research progress of potassium-competitive acid blockers in the treatment of
Helicobacter pylori
. Annals of Medicine 2025; 57(1) doi: 10.1080/07853890.2025.2544886
|
| 3 |
Azzam Zrineh, Rami Akwan, Muhammad M. Elsharkawy, Mostafa Adel T. Mahmoud, Hadeel Ayesh, Mazen Momtaz Shehata, Hamza Karmi, Elsayed S. Moubarak. Assessing the non-inferiority of a 10-day compared with a 14-day vonoprazan–amoxicillin dual therapy regimen for H. pylori eradication: a systematic review and meta-analysis. BMC Infectious Diseases 2026; 26(1) doi: 10.1186/s12879-026-13085-0
|
| 4 |
Zhiqiang Song, Xiuli Zuo, Zhenyu Zhang, Xuehong Wang, Ya Lin, Yueyue Li, Xiaojun Xu, Yun Huang, Qiuyan Wang, Yanyan Shi, Liya Zhou. Ten‐Day Versus 14‐Day Vonoprazan and Amoxicillin Dual Therapy for the Firstline Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial. Helicobacter 2025; 30(5) doi: 10.1111/hel.70070
|
| 5 |
Chih-An Shih, Deng-Chyang Wu, Chang-Bih Shie, Ping-I Hsu. Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan for Helicobacter pylori Infection: A Systematic Review. Microorganisms 2025; 13(4) doi: 10.3390/microorganisms13040715
|
| 6 |
Te-Ling Ma, Chun-Ying Huang, Chen-Ya Kuo, Kuang-Yi Sung, Yu-Tse Chiu, Po-Rui Wu, Fu-Jen Lee, Kai-Shun Liang, Kuan-Wei Wu, Yu-Tsung Chen, Yen-Po Liou, Chi-Yang Chang. Fourteen-day vonoprazan-based dual therapy with amoxicillin as first-line Helicobacter pylori treatment in comparison with sequential therapy: A randomized controlled trial. Journal of the Formosan Medical Association 2026; doi: 10.1016/j.jfma.2026.04.082
|
| 7 |
Changmin Mi, Kai Zhou, Yanyan Shi, Kailun Liang, Fang Zhou, Zhiqiang Song. Comparing potassium-competitive acid blocker-based therapies for Helicobacter pylori infection: A Bayesian network meta-analysis of 77 randomised controlled trials. Frontiers in Physiology 2026; 17 doi: 10.3389/fphys.2026.1843686
|
| 8 |
Jin-Yan Zhang, Jin-Hai Chen, Yu-Lin Huang, Ji Li, Dong Xu, Zhong Xu, Xiao-Yi Lei.
Fourteen-day vonoprazan-amoxicillin dual therapy versus 14-day bismuth-based quadruple therapy for
Helicobacter pylori
treatment: a randomized clinical trial
. Therapeutic Advances in Gastroenterology 2025; 18 doi: 10.1177/17562848251354868
|
| 9 |
Emad Abdelrazzik Muhammadien, Amany Mahmoud Ismaiel, Abdelwahab Fathi Ali Ahmed, Amira Abdel Naby Qotop Osman. Efficacy of vonoprazan versus omeprazole in high-dose amoxicillin dual regimen for eradication of Helicobacter pylori infection: A randomized controlled trial. Al-Azhar Assiut Medical Journal 2026; 24(1) doi: 10.4103/azmj.azmj_116_25
|
| 10 |
Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Mariana Macambira Noronha, Melissa Cortez Braga Maia, Guilherme Grossi Lopes Cançado. Eradication of Helicobacter pylori With Vonoprazan–Amoxicillin Dual Therapy as an Alternative for Bismuth‐Based Quadruple Therapy: A Systematic Review and Noninferiority Meta‐Analysis. Journal of Gastroenterology and Hepatology 2026; doi: 10.1111/jgh.70565
|
| 11 |
Zafeer-ul-Hassan Iqbal, Syed Muhammad Hassan Bukhari, Shama Shahid Rana, Rana Asjad Dilshad, Amna Saeed, Mars Christian Aragon Sta Ines, Ali Haroon. Comparison of Vonoprazan Triple Therapy, Bismuth Quadruple Therapy, and Amoxicillin Therapy for Helicobacter pylori Infection: A Systematic Review. Cureus 2025; doi: 10.7759/cureus.83142
|
| 12 |
Chih-An Shih, I-Ting Wu, Deng-Chyang Wu, Wei-Yi Lei, Feng-Woei Tsay, Tzung-Jiun Tsai, Chung-Hung Tsai, Ya-Chi Wu, Wei-Chen Tai, Ping-I Hsu. Evolution of Amoxicillin-Based Mono-Antibiotic Regimens for Helicobacter pylori Eradication: From Ineffectiveness to Innovation—A Systematic Review. Microorganisms 2026; 14(3) doi: 10.3390/microorganisms14030625
|
| 13 |
Ming-ming Zhang, Mei-ding Wang, Shi-yu Yang, Jia-qiang Hu, Bao-qiang Zhu, Yuan-kui Wei, Chang-lan Zhang, En-wu Long. The efficacy and safety of vonoprazan-based high-dose dual therapy for eradication of Helicobacter pylori: A systematic review and meta-analysis. Journal of Infection and Public Health 2025; 18(7) doi: 10.1016/j.jiph.2025.102768
|
| 14 |
Xueyan Lin, Huping Huang, Yijuan Liu, Yanling Zeng, Shiyun Lu, Xuefeng Xu, Yun Lin, Feng Qiu, Fangfang Cai, Jie Pan, Shaozhong Huang, Shaowei Lin, Aiping Lin, Zhihui Lin, Xueping Huang. Tegoprazan‐Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China. Helicobacter 2024; 29(6) doi: 10.1111/hel.13151
|